Company Overview
| Stock Name | Yzybio-B |
|---|---|
| Stock Code | 02496 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家致力于開發用于治療癌癥相關并發癥、癌癥及老年性眼科疾病的BsAb療法的生物技術公司。 |
| Listing Date | 2023-09-25 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國湖北省武漢市東湖新技術開發區高新大道666號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.yzybio.com/ |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 16.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 59.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 17,603,200 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 3,200 |
| 2 lots | 400 | HK$ 6,400 |
| 3 lots | 600 | HK$ 9,600 |
| 4 lots | 800 | HK$ 12,800 |
| 5 lots | 1,000 | HK$ 16,000 |
| 6 lots | 1,200 | HK$ 19,200 |
| 7 lots | 1,400 | HK$ 22,400 |
| 8 lots | 1,600 | HK$ 25,600 |
| 9 lots | 1,800 | HK$ 28,800 |
| 10 lots | 2,000 | HK$ 32,000 |
| 15 lots | 3,000 | HK$ 48,000 |
| 20 lots | 4,000 | HK$ 64,000 |
| 25 lots | 5,000 | HK$ 80,000 |
| 30 lots | 6,000 | HK$ 96,000 |
| 35 lots | 7,000 | HK$ 112,000 |
| 40 lots | 8,000 | HK$ 128,000 |
| 45 lots | 9,000 | HK$ 144,000 |
| 50 lots | 10,000 | HK$ 160,000 |
| 75 lots | 15,000 | HK$ 240,000 |
| 100 lots | 20,000 | HK$ 320,000 |
| 125 lots | 25,000 | HK$ 400,000 |
| 150 lots | 30,000 | HK$ 480,000 |
| 175 lots | 35,000 | HK$ 560,000 |
| 200 lots | 40,000 | HK$ 640,000 |
| 250 lots | 50,000 | HK$ 800,000 |
| 300 lots | 60,000 | HK$ 960,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | None |
|---|---|
| Avg Daily HK Mkt Cap | --- |
| Est. Threshold | --- |
| Analysis Result | 无法确定入通路径 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 16.0 |
|---|---|
| First Day Open | HK$ 16.4 |
| First Day Change | -67.75% |
| First Day Volume | 1519600.0 |
| First Day Turnover | 24912300.0 |
| Use of Proceeds | 1、約80%或約97.1百萬港元將用作核心產品M701計劃進行的臨床試驗、擬備注冊備案文件及商業化推出計劃;
2、約12%或14.6百萬港元將用作Y101D計劃進行的臨床試驗;
3、約8%或9.7百萬港元將用作營運資金和一般公司用途。 |
Underwriting Syndicate
Sole Sponsor (1)
中信建投(国际)融资有限公司 CE BAU112
Joint Bookrunners (6)
Joint Lead Managers (8)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 成都朴华凯智生物科技有限公司 | 21,481,600 HKD | — | 12.20% | — | 6 months | 2024-03-25 |
| 2 | 武汉光谷健康产业投资有限公司 | 42,976,000 HKD | — | 24.42% | — | 6 months | 2024-03-25 |
| 3 | 武汉市楚兴友瑞大健康产业投资基金合伙企业(有限合伙) | 39,763,200 HKD | — | 22.59% | — | 6 months | 2024-03-25 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | Zhou Pengfei | — |
| Company Secretary | 鄭建華;賴天恩 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 袁謙(10.57%);武漢才智投資管理合伙企業(有限合伙)(8.70%);周宏峰(5.28%) |
|---|




